Launch week offerEnds in00h00m00s

annual Promonthly Pro

Ozan Kumru

Scientific Associate Director

University of Kansas

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Collaborators (5)

Peter S. Kim

Stanford University School of Medicine

UNITED STATES

David B. Volkin

University of Kansas

UNITED STATES

Mrinmoy Sanyal

Stanford University

UNITED STATES

Prabhu S Arunachalam

Assistant Professor

University of Arizona

UNITED STATES

Mengyun Hu

Stanford University

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ozan Kumru

Research Interests

Make your next move.

Explore related searches

Articles (12)

Collaborators (5)

Peter S. Kim

David B. Volkin

Mrinmoy Sanyal

Prabhu S Arunachalam

Mengyun Hu

Make your next move.

Ozan Kumru

Research Interests

Make your next move.

Explore related searches

Articles (12)

Formulation and Delivery Strategies for Current and Next-Generation Live-Attenuated Measles and Rubella Containing Vaccines [version 1]

Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons-Learned for Future Technology Transfer [version 1]

Development of a New Lyophilized Live-Attenuated Measles-Rubella (MR) Vaccine Formulation Designed for Lower Cost Production in Africa [version 1]

Two recombinant cytomegalovirus antigens formulated with the SPA14 adjuvant system: Impact of temperature, pH and excipients on the stability of each antigen and adjuvant component

Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles [version 1]

Characterizing the Aggregation Propensity of an Anti-HIV-1 Bispecific Antibody in Two Different Formulation Buffers During Agitation Stress [version 1]

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli

Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations

Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies

Collaborators (5)

Peter S. Kim

David B. Volkin

Mrinmoy Sanyal

Prabhu S Arunachalam

Mengyun Hu

Make your next move.